Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats

Circulation Journal

Volumn 81, Issue 3, 2017, Pages 405-412

  Hekmat, Ava Soltani ^a   Javanmardi, Kazem ^a   Kouhpayeh, Amin ^a   Baharamali, Ehsan ^a   Farjam, Mojtaba ^a  

^a FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

2K1C; Alamandine; Hypertension; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ALAMANDINE; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; LOSARTAN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INFUSION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY; MALE; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM;

EID: 85013943876     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0958     Document Type: Article

References (34)

1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008; 52: 818–827.
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A–9A; discussion 10A.
3. Brunner HR, Gavras H, Turini GA, Waeber B, Cappuis P, McKinstry DN. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. Clin Sci Mol Med Suppl 1978; 4: 293s–295s.
4. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–752.
5. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. Discovery and characterization of alamandine: A novel component of the renin-angiotensin system. Circ Res 2013; 112: 1104–1111.
6. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted A, et al. Angiotensin-(1–7): A new hormone of the angiotensin system. Hypertension 1991; 18(Suppl 5): 3126–3133.
7. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258–8268.
8. Santos RA, Ferreira AJ, Simões E, Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis. Exp Physiol 2008; 93: 519–527.
9. Hrenak J, Paulis L, Simko F. Angiotensin A/Alamandine/MrgD axis: Another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 2016; 17: pii. E1098.
10. Etelvino GM, Peluso AA, Santos RA. New components of the renin-angiotensin system: Alamandine and the MAS-related G protein-coupled receptor D. Curr Hypertens Rep 2014; 16: 433.
11. Soltani Hekmat A, Najafipour H, Nekooian AA, Esmaeli-Mahani S, Javanmardi K. Cardiovascular responses to apelin in two-kidney–one-clip hypertensive rats and its receptor expression in ischemic and non-ischemic kidneys. Regul Pept 2011; 172: 62–68.
12. Najafipour H, Vakili A, Shahouzehi B, Soltani Hekmat A, Masoomi Y, Hajahmadi MY, et al. Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension. J Physiol Biochem 2015; 71: 165–175.
13. Rowe BP, Nasjletti A. Biphasic blood pressure response to angiotensin II in the conscious rabbit: Relation to prostaglandins. J Pharmacol Exp Ther 1983; 225: 559–563.
14. Scheuer DA, Perrone MH. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993; 264: R917 – R923.
15. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744–747.
16. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27: 760–765.
17. Haulica I, Bild W, Mihaila CN, Ionita T, Boisteanu CP, Neagu B. Biphasic effects of angiotensin (1 – 7) and its interactions with angiotensin II in rat aorta. J Renin Angiotensin Aldosterone Syst 2003; 4: 124–128.
18. Barry WH, Bridge J. Intracellular calcium homeostasis in cardiac myocytes. Circulation 1993; 87: 1806–1815.
19. Aartsen WM, Smits FM, Daemen MAP. Activation of the reninangiotensin system after myocardial infarction. In: Unger T, Schölkens BA, editors. Angiotensin vol 2. Heidelberg: Springer, 2004; 237–254.
20. Höcht C, Mayer M, Taira CA. Therapeutic perspectives of angiotensin-(1–7) in the treatment of cardiovascular disease. Open Pharmacol J 2009; 3: 21–31.
21. Marie E, Sandberg K. Angiotensin AT 1 receptor signal transduction. In: Unger T, Schölkens BA, editors. Angiotensin vol 1. Heidelberg: Springer, 2004; 335–350.
22. Sibbald WJ, Driedger AA. Right ventricular function in acute disease states: Pathophysiologic considerations. Crit Care Med 1983; 11: 339–345.
23. Villela DC, Passos-Silva DG, Santos RA. Alamandine: A new member of the angiotensin family. Curr Opin Nephrol Hypertens 2014; 23: 130–134.
24. Tetzner A, Gebolys K, Meinert C, Klein S, Uhlich A, Trebicka J, et al. G-protein-coupled receptor MrgD is a receptor for angiotensin-(1–7) involving adenylyl cyclase, cAMP, and phos-phokinase A. Hypertension 2016; 68: 185–194.
25. Nahmias E, Boden E. Molecular aspects of AT2 receptor. In: Unger T, Schölkens BA, editors. Angiotensin vol 1. Heidelberg: Springer, 2004; 375–398.
26. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Cell Physiol 2007; 292: C82–C97.
27. Abdel-Rahman EM, Siragy HM. AT2 renal aspects. In: Unger T, Schölkens BA, editors. Angiotensin vol 1. Heidelberg: Springer, 2004; 423–448.
28. Inuzuka T, Fujioka Y, Tsuda M, Fujioka M, Satoh AO, Horiuchi K, et al. Attenuation of ligand-induced activation of angiotensin II type 1 receptor signaling by the type 2 receptor via protein kinase C. Sci Rep 2016; 6: 21613.
29. Nickenig G, Laufs U, Schnabel P, Knorr A, Paul M, Bohm MP. Down-regulation of aortic and cardiac AT1 receptor gene expression in transgenic (mRen-2) 27 rats. Br J Pharmacol 1997; 121: 134–140.
30. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984; 246: H608–H614.
31. Aguilera G, Catt K. Regulation of vascular angiotensin II receptors in the rat during altered sodium intake. Circ Res 1981; 49: 751 – 758.
32. Faria-Costa G, Leite-Moreira A, Henriques-Coelho T. Cardiovascular effects of the angiotensin type 2 receptor. Rev Port Cardiol 2014; 33: 439–449.
33. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 2005; 45: 967–973.
34. Amiri F, Garcia R. Renal angiotensin II receptor regulation in two-kidney, one clip hypertensive rats effect of ace inhibition. Hypertension 1997; 30: 337–344.